When does ResMed report earnings and why does it matter for RMD.AX stock?

ResMed reports on 29 Jan 2026 after markets close. The report matters because it updates device and mask sales, software revenue and guidance. These items directly affect RMD.AX stock valuation and near-term trading on the ASX.

What is Meyka AI's price forecast for RMD.AX stock?

Meyka AI's forecast model projects **A$44.22** for the next 12 months versus the current **A$37.60**, implying a **17.61%** upside. Forecasts are model-based projections and not guarantees.

Which metrics should investors watch in ResMed’s earnings?

Focus on Masks and Devices revenue growth, Software-as-a-Service monthly recurring revenue and margin trends, EPS vs consensus, and management guidance. These metrics typically drive immediate moves in RMD.AX stock.

How is ResMed valued compared to the healthcare sector?

ResMed’s PE near **26.67** sits below the ASX healthcare average PE of **34.06**, indicating a relative earnings multiple discount despite robust margins and free cash flow metrics for RMD.AX stock.

AU Stocks

A$37.60 pre-market for ResMed (RMD.AX): Jan 29 earnings to shape guidance

ByDanny Kontos January 28, 2026January 28, 2026

ResMed Inc. (RMD.AX) trades at A$37.60 in pre-market trade on 28 Jan 2026 as investors position ahead of the company’s Jan 29, 2026 earnings release. RMD.AX stock faces a test on growth and margins with consensus expecting revenue near US$1.39bn and EPS around US$2.68 for the quarter. Market focus will be on mask resupply strength, device demand and software subscription momentum as the report can swing sentiment into the ASX trading session.